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Systemic sclerosis (SSc, scleroderma) is characterized by fibrosis of the skin and 
internal organs, autoantibodies and diffuse microangiopathy. In SSc, fibrillin-1 
microfibrils are disorganized and unstable. Mutations in FBN1 gene and anti-fibril-
lin-1 autoantibodies have also been reported in SSc patients. Fibrillin-1 microfibrils 
sequester in the extracellular matrix the latent form of the potent pro-fibrotic cytokine 
transforming growth factor-β (TGF-β). We herein report the effects of SSc sera on the 
deposition of fibrillin-1 and microfibril-associated glycoprotein-1 (MAGP-1) and the 
expression of focal adhesion molecules by dermal blood (B-MVECs) and lymphatic 
(Ly-MVECs) microvascular endothelial cells. Cells were challenged with sera from 
SSc patients, naïve or under cyclophosphamide (CYC) treatment, and healthy con-
trols. Fibrillin-1/MAGP-1 synthesis and deposition and the expression of αvβ3 integ-
rin/phosphorylated-FAK and vinculin/actin were evaluated by immunofluorescence 
and quantified by morphometric analysis. Fibrillin-1 and MAGP-1 co-localized in 
all experimental conditions, forming a honeycomb pattern in B-MVECs and a dense 
mesh of short segments in Ly-MVECs. In B-MVECs, fibrillin-1/MAGP-1 production 
and αvβ3 integrin expression significantly decreased upon challenge with sera from 
naïve SSc patients compared with healthy controls. Vinculin was overexpressed in the 
cells exposed to the serum of naïve patients with the diffuse form of SSc. B-MVECs 
challenged with sera from CYC-treated SSc patients showed fibrillin-1, αvβ3 integrin 
and vinculin levels comparable to those of controls. Ly-MVECs challenged with SSc 
sera did not differ from controls in the expression of any of the molecules assayed. 
Due to the critical role of fibrillin-1 in sequestering TGF-β in the extracellular matrix, 
its decreased deposition by B-MVECs challenged with SSc sera might contribute to 
dermal fibrosis. CYC treatment might limit fibrosis through the maintenance of phys-
iologic fibrillin-1 synthesis and deposition by B-MVECs. CYC-induced normalization 
of αvβ3 integrin expression may restore effective interaction of endothelial cells with 
fibrillin. Since vinculin is necessary for angiogenesis, its normalization upon CYC 
treatment may contribute to restore the impaired angiogenesis found in SSc. 
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